What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand
Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.
Pharma & Biotech
Pharma & Biotech
Why Vetter’s Saarlouis expansion matters for sterile injectable supply chains
Injectable capacity is tightening. Vetter’s Saarlouis bet shows why Europe wants more control over sterile drug manufacturing.
Pharma & Biotech
How AstraZeneca’s Owkin deal could push agentic AI deeper into drug development
Pharma has too much data and too little time. AstraZeneca’s Owkin deal tests whether agentic AI can sharpen drug development decisions.
Pharma & Biotech
EU backs Pfizer’s Hympavzi for hemophilia patients with inhibitors. What changes now?
Hemophilia care is moving beyond factor replacement. Pfizer’s Hympavzi EU expansion tests how far anti-TFPI therapy can scale.
Pharma & Biotech
Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?
Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.
Pharma & Biotech
Why Sapu Nano’s Deciparticle platform could become a broader oncology drug-delivery play
Discover how Sapu Nano’s Deciparticle platform could reshape oncology drug delivery and expand intravenous everolimus development.
Pharma & Biotech
How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation
How is PharmAla Biotech Holdings Inc. positioning APA-01 for traumatic brain injury and neurorehabilitation markets? Read the full PDN analysis.
Pharma & Biotech
What Can-Fite BioPharma Ltd.’s Phase 2b pancreatic cancer strategy reveals about immunotherapy combination economics
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
Pharma & Biotech
Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?
Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.
Pharma & Biotech
FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity
Rare cancer biology met regulatory urgency. Bizengri’s approval tests whether precision oncology can reach tiny patient subsets fast.